UK-based pharmaceutical major GlaxoSmithKline has received approval for its Revolade and Xyzal medications from the Japanese Ministry of Health, Labour and Welfare.

Revolade is the world’s first oral treatment used to stimulate the production of blood platelets, and is used to treat the blood disorder chronic idiophatic thrombocytopenic purpura.

Anti-allergic drug Xyzal has been given approval for the treatment of allergic rhinitis, urticaria, eczema and dermatitis in patients over the age of seven.